ECE2023 Poster Presentations Pituitary and Neuroendocrinology (123 abstracts)
Mortality in acromegaly diagnosed in the elderly in Spain is higher in women compared to the general Spanish population
Betina Biagetti 1 , Pedro Iglesias 2 , Rocio Villar Taibo 3 , María Dolores Moure 4 , Miguel Paja Fano 5 , Marta Araujo Castro 6 , Jessica Ares Blanco 7 , Maria Cristina Alvarez Escola 8 , Almudena Vicente 9 , Èlia Álvarez Guivernau 10 , Iria Novoa-Testa 11 , Fernando Cordido Carballido 11 , Rosa Camara-Gómez 12 , Beatriz Lecumberri 8 , Carlos García Gómez 2 , Ignacio Bernabeu 3 , Laura Manjon Miguelez 7 , Sonia Gaztambide 4 , Susan Webb 10 , Edelmiro Luis Menendez Torre 7 , Juan Jose Diez 2 , Rafael Simo Canonge 1 & Manel Puig-Domingo 13
1Hospital Universitari Vall d’Hebron, Barcelona, Spain; 2Puerta de Hierro Majadahonda University Hospital, Majadahonda, Spain; 3Santiago Clinic Hospital CHUS, Santiago de Compostela, Spain; 4University Hospital of the Crosses, Barakaldo, Spain; 5Basurto University Hospital, Bilbo, Spain; 6Ramón y Cajal Hospital, Madrid, Spain; 7Central University Hospital of Asturias, Oviedo, Spain; 8La Paz University Hospital, Madrid, Spain; 9Hospital General Universitario de Toledo, Toledo, Spain; 10Sant Pau Art Nouveau Site, Barcelona, Spain; 11[CHUAC] University Hospital of A Coruña, A Coruña, Spain; 12Hospital la Fe, Valencia, Spain; 13Germans Trias i Pujol Hospital, Badalona, Spain
Context: There is no data on mortality of acromegaly diagnosed in the elderly.
Objective: To compare clinical characteristics, GH-related comorbidities, therapeutic approaches and mortality of patients diagnosed before or after 2010 and to assess overall mortality compared with the general Spanish population.
Setting: Spanish tertiary care centers.
Design, Patients, and Methods: Retrospective evaluation of 118 patients diagnosed with acromegaly at or above the age of 65. Kaplan-Meier curves were constructed to trace survival, and Cox proportional hazard models were used to assess the risk factors associated with mortality. We also compared mortality with that of the Spanish population by using age- and gender-adjusted standardized mortality ratios (SMR)
Results: No differences were found in first-line treatment or biochemical control, between both periods except for faster biochemical control after 2010. Twenty-nine (24.6%) patients died, without differences between groups, median of follow-up 8.6 years [103, (72.3) months]. Overall SMR was 1.02 (95% CI: 0.57–1.54), [0.60 (95% CI: 0.35–1.06) for men] and [1.80 (95% CI: 1.07–2.94) for women]. The most common cause of death was cardiovascular disease (CVD).
Conclusions: The mortality in patients with acromegaly diagnosed in the elderly was no different between both periods and there was no overall SMR difference from the general Spanish population. However, the SMR was higher in women. As CVD is the leading cause of mortality, it seems advisable to initiate an intense CVD protective treatment as soon as acromegaly is diagnosed, particularly in women, in addition to tight acromegaly control in order to prevent excess mortality.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more